Intravenous pantoprazole versus ranitidine for prevention of rebleeding after endoscopic hemostasis of bleeding peptic ulcers

Table 1 Base-line characteristics of the study patients with bleeding peptic ulcers n (%)

	Pantoprazole group (n = 52)	Ranitidine group (n = 50)	P
Age (yr) (SD)	63.2 (18.2)	64.7 (13.8)	0.64
Gender (M:F)	41:11	37:13	0.56
Smoking	17 (32.7)	16 (32.0)	0.94
Alcohol abuse	7 (13.5)	4 (8.0)	0.37
NSAID use	14 (26.9)	16 (32.0)	0.57
History of ulcer	32 (61.5)	28 (56.0)	0.57
History of ulcer bleeding	14 (26.9)	9 (18.0)	0.28
Hypovolemic shock	3 (5.8)	3 (6.0)	1.00
Hemoglobin (g/dL) (SD)	10.3 (3.0)	10.0 (2.8)	0.68
Endoscopic findings
Ulcer size (cm) (SD)	1.2 (0.8)	1.2 (0.6)	0.79
Ulcer site			0.85
Stomach	25 (48.1)	25 (50.0)
Duodenum	27 (51.9)	25 (50.0)
Bleeding activity
Spurting vessel	4 (7.7)	2 (4.0)	0.64
Oozing vessel	18 (34.6)	17 (34.0)
Nonbleeding visible vessel	18 (34.6)	21 (42.0)
Adherent clot	12 (23.1)	10 (20.0)

Table 2 Clinical outcomes of pantoprazole and ranitidine groups n (%)

	Pantoprazole group (n = 52)	Ranitidine group (n = 50)	P
Rebleeding	2 (3.8)	8 (16.0)	0.041
Emergency operation	0 (0.0)	1 (2.0)	0.31
Hospital days (SD)	5.9 (3.2)	7.5 (5.0)	0.06
Units of Blood transfusion (SD)	4.9 (5.8)	5.7 (6.8)	0.42
Mortality	1 (1.9)	1 (2.0)	1.00

¹Significant difference.